kisspeptin-10 vs pt-141

kisspeptin-10 (B-tier) vs pt-141 (A-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

kisspeptin-10 — tier B

kisspeptin-family pharmacology with real HSDD and fertility signals. the strongest human trials used kisspeptin-54, not the KP-10 vial market.

the kisspeptin family has unusually clean human trial data for sexual medicine and IVF. the strongest trials used kisspeptin-54, not the KP-10 vial market.

KP-54 strong trials use a different analog · half-life short, approximately 4-5 minutes in plasma (full kisspeptin-54 is the longer-acting parent) · libido

pt-141 — tier A

the FDA-approved sex peptide for acquired generalized HSDD in premenopausal women. off-label male use is a separate evidence lane.

FDA-approved as Vyleesi for HSDD in premenopausal women. the louder cultural use case (male PDE5 non-responders) is off-label and being formally tested.

FDA '19 Vyleesi · HSDD · half-life ~2 hours (peak central effect 45-60 min) · libido

at a glance

• kisspeptin-10: tier B · KP-54 strong trials use a different analog
• pt-141: tier A · FDA '19 Vyleesi · HSDD

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.